title: [Clinical efficacy of bushen huoxue qubi decoction on treatment of knee-osteoarthritis and its effect on hemarheology, anti-inflammation and antioxidation].
abstract: OBJECTIVE
  To prove the clinical effect and mechanism of Bushen Huoxue Qubi Decoction on treatment of knee-osteoarthritis.
  
  
  METHODS
  Ninty-six knee-osteoarthritic patients accompanied with symptoms of liver and kidney deficiency and blocked main and collateral channels were divided into two groups randomly. Patients in the treatment group (n = 48) were administrated by Bushen Huoxue Qubi Decoction one bag/day for four weeks; and those in the control group (n = 48) were given diacerein (50 mg Bid, Po) and celecoxib (0.2 Qd, Po) for four weeks. The changes of VAS score, Womac score, relative viscosity, aggregation index and IL-1beta, NO, iNOS, LPO, SOD in serum were observed. Adverse effects were determined during follow-up visit and detection for blood routine and hepatic and renal functions.
  
  
  RESULTS
  Its clinical control rates as per Western medicine and TCM standards for treatment of knee-osteoarthritis and effective rate were 33.3%, 37.5% and 97.9% respectively, which was remarkably higher than those in the control group (18.8%, 20.8% and 95.5%). Their difference showed statistical significance, P<0.05 or 0.01. Bushen Huoxue Qubi Decoction had an effect in obviously improving hemarheological index in 42 days and inhibiting IL-1beta, NO, iNOS and LPO better than the control group, by the contrast of 58.6% vs 47.3%, 50.1% vs 36%, 55.1% vs 41.9% and 46.7% vs 20.6% (P<0.05 or P<0.01). The treatment group also displayed a higher SOD capability the control group (2 514.71 +/- 812.65) vs (2 013.41 +/- 781.3), (P<0.01). Both groups reported no adverse effect.
  
  
  CONCLUSIONS
  Bushen Huoxue Qubi Decoction has a better efficacy on knee-OA than traditional treatment methods (diacereinand + celecoxib) and showed no adverse effect.
authors.affiliation: Department of Laboratory Medicine, Xiangya Medical College of Central South University, Changsha 410013, China ggboxy@163.com
authors.forename: Ge
authors.initials: G
authors.lastname: Gao
authors.forename: Hong
authors.initials: H
authors.lastname: Wu
authors.forename: Jing
authors.initials: J
authors.lastname: Tian
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Du
authors.forename: Xi
authors.initials: X
authors.lastname: Xie
authors.forename: Jiesheng
authors.initials: J
authors.lastname: Gao
mesh_terms: D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016022:Case-Control Studies; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood; D052247:Nitric Oxide Synthase Type II / Q000097:blood; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D000975:Antioxidants; D004365:Drugs, Chinese Herbal; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; C527851:bushen huoxue; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II